120017
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.6 Breast Cancer (Dove Med Press)
- 4.3 Clin Epidemiol
- 2.6 Cancer Manag Res
- 3.2 Infect Drug Resist
- 4.1 Clin Interv Aging
- 6.1 Drug Des Dev Ther
- 4.1 Int J Chronic Obstr
- 8.7 Int J Nanomed
- 2.5 Int J Women's Health
- 3.2 Neuropsych Dis Treat
- 2.4 OncoTargets Ther
- 2.6 Patient Prefer Adher
- 2.6 Ther Clin Risk Manag
- 3.1 J Pain Res
- 3.5 Diabet Metab Synd Ob
- 4.5 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 2.4 Pharmgenomics Pers Med
- 2.6 Risk Manag Healthc Policy
- 4.6 J Inflamm Res
- 2.3 Int J Gen Med
- 3.9 J Hepatocell Carcinoma
- 3.3 J Asthma Allergy
- 2.5 Clin Cosmet Investig Dermatol
- 3.0 J Multidiscip Healthc
已发表论文
IP-10/CXCL10在肝损伤中的双重作用：从致病介质到临床生物标志物和治疗靶点
Authors Yang J , Huang Y, Yuan Y, Yan D
Received 28 August 2025
Accepted for publication 11 January 2026
Published 22 January 2026 Volume 2026:20 544545
DOI https://doi.org/10.2147/DDDT.S544545
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Solomon Tadesse Zeleke
Jiezuan Yang,1,2 Yandi Huang,3 Yingying Yuan,1,2 Dong Yan1,2
1The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, People’s Republic of China; 2State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Hangzhou, 310003, People’s Republic of China; 3Department of Laboratory Medicine, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, People’s Republic of China
Correspondence: Jiezuan Yang, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, People’s Republic of China, Tel +86 571 87236756, Email yangyan@zju.edu.cn
Abstract: A complex interplay of immune and inflammatory mechanisms underlies liver injury, with the chemokine interferon-gamma-induced protein 10 (IP-10/CXCL10) playing a decisive role. Recent findings identify IP-10 as a key pathogenic mediator; by binding its receptor CXCR3, it directly recruits cytotoxic T lymphocytes and NK cells to the liver, promoting hepatocyte apoptosis and driving inflammation. This chemokine also activates hepatic stellate cells (HSCs), stimulating fibrogenesis and disease progression in conditions ranging from viral hepatitis to metabolic steatotic liver disease (MASLD) and cirrhosis. Consequently, IP-10 has emerged as a sensitive biomarker for liver inflammation and fibrosis. This review highlights these mechanistic insights, linking CXCL10’s causal roles to its diagnostic, prognostic, and therapeutic potential. We examine its utility in early detection, risk stratification, and targeted therapies to modulate immune responses and reduce fibrosis. We also discuss innovative applications in personalized medicine and precision diagnostics that offer new opportunities to improve outcomes in viral hepatitis and other liver diseases. By integrating mechanistic understanding with clinical implications, this work clarifies the multifaceted role of CXCL10 and identifies future research directions to optimize its therapeutic and diagnostic applications.
Keywords: clinical value, CXCR3, IP-10, liver injury, mechanism
1The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, People’s Republic of China; 2State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Hangzhou, 310003, People’s Republic of China; 3Department of Laboratory Medicine, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, People’s Republic of China
Correspondence: Jiezuan Yang, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, People’s Republic of China, Tel +86 571 87236756, Email yangyan@zju.edu.cn
Abstract: A complex interplay of immune and inflammatory mechanisms underlies liver injury, with the chemokine interferon-gamma-induced protein 10 (IP-10/CXCL10) playing a decisive role. Recent findings identify IP-10 as a key pathogenic mediator; by binding its receptor CXCR3, it directly recruits cytotoxic T lymphocytes and NK cells to the liver, promoting hepatocyte apoptosis and driving inflammation. This chemokine also activates hepatic stellate cells (HSCs), stimulating fibrogenesis and disease progression in conditions ranging from viral hepatitis to metabolic steatotic liver disease (MASLD) and cirrhosis. Consequently, IP-10 has emerged as a sensitive biomarker for liver inflammation and fibrosis. This review highlights these mechanistic insights, linking CXCL10’s causal roles to its diagnostic, prognostic, and therapeutic potential. We examine its utility in early detection, risk stratification, and targeted therapies to modulate immune responses and reduce fibrosis. We also discuss innovative applications in personalized medicine and precision diagnostics that offer new opportunities to improve outcomes in viral hepatitis and other liver diseases. By integrating mechanistic understanding with clinical implications, this work clarifies the multifaceted role of CXCL10 and identifies future research directions to optimize its therapeutic and diagnostic applications.
Keywords: clinical value, CXCR3, IP-10, liver injury, mechanism